Ki67 and CD31 Differential Expression in Cutaneous T-Cell Lymphoma and Its Mimickers: Association with Clinicopathological Criteria and Disease Advancement.
CD31
Ki67
TNMB stage
cutaneous T-cell lymphoma
mycosis fungoides
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
03
2020
accepted:
04
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Cell proliferation and angiogenesis are important in progression of cancerous processes. Differentiating cutaneous T-cell lymphoma (CTCL) from its mimicking dermatoses and prognosticating it are challenging. This study assesses cell proliferation and angiogenesis in different CTCL subtypes using immunohistochemistry (IHC) for Ki67 and CD31 to testify their usability in differentiating CTCL from mimicking dermatoses and discriminating CTCL subtypes from each other with correlation to clinicopathological parameters and disease advancement. IHC for Ki67 and CD31 were applied to skin biopsies from 81 patients divided into CTCL (n=59) and dermatoses (n=22) groups. Hot-spot analysis was used to score Ki67 and CD31 microvascular density (MVD) semiquantitatively. Statistical analysis was performed to compare Ki67 index and MVD between CTCL and dermatoses. CTCL subgroups were compared to each other. Ki67 index and CD31 were compared to age, gender, skin and nodal involvement, blood tumor burden and TNMB stage. There were significant differences in proliferation index and MVD between dermatoses and CTCL, and between dermatoses and all CTCL subtypes with exception of Ki67 in early mycosis fungoides (MF) and CD31 in patch lesions. Increased cell proliferation and MVD were significantly associated with older age, T3 and 4 skin involvement, significant nodes (N1-3), positive blood tumor burden (B1,2) in CTCL and TNMB stage of MF. Both markers differentiated significantly late from early MF, classic MF from its variants and non-MF CTCL from total MF, but not from late MF. In conclusion, Ki67 and CD31 expression in skin biopsies using IHC reproduces the role of proliferation and angiogenesis in the differential diagnosis and prognostication of CTCL being expressed at higher levels in aggressive than indolent CTCL. Therapeutic targeting of cell proliferation and angiogenesis may improve patient's outcome in CTCL. Usability of these markers into patient's stratification should be considered in further studies.
Sections du résumé
BACKGROUND
BACKGROUND
Cell proliferation and angiogenesis are important in progression of cancerous processes. Differentiating cutaneous T-cell lymphoma (CTCL) from its mimicking dermatoses and prognosticating it are challenging.
AIM
OBJECTIVE
This study assesses cell proliferation and angiogenesis in different CTCL subtypes using immunohistochemistry (IHC) for Ki67 and CD31 to testify their usability in differentiating CTCL from mimicking dermatoses and discriminating CTCL subtypes from each other with correlation to clinicopathological parameters and disease advancement.
PATIENTS AND METHODS
METHODS
IHC for Ki67 and CD31 were applied to skin biopsies from 81 patients divided into CTCL (n=59) and dermatoses (n=22) groups. Hot-spot analysis was used to score Ki67 and CD31 microvascular density (MVD) semiquantitatively. Statistical analysis was performed to compare Ki67 index and MVD between CTCL and dermatoses. CTCL subgroups were compared to each other. Ki67 index and CD31 were compared to age, gender, skin and nodal involvement, blood tumor burden and TNMB stage.
RESULTS AND CONCLUSION
CONCLUSIONS
There were significant differences in proliferation index and MVD between dermatoses and CTCL, and between dermatoses and all CTCL subtypes with exception of Ki67 in early mycosis fungoides (MF) and CD31 in patch lesions. Increased cell proliferation and MVD were significantly associated with older age, T3 and 4 skin involvement, significant nodes (N1-3), positive blood tumor burden (B1,2) in CTCL and TNMB stage of MF. Both markers differentiated significantly late from early MF, classic MF from its variants and non-MF CTCL from total MF, but not from late MF. In conclusion, Ki67 and CD31 expression in skin biopsies using IHC reproduces the role of proliferation and angiogenesis in the differential diagnosis and prognostication of CTCL being expressed at higher levels in aggressive than indolent CTCL. Therapeutic targeting of cell proliferation and angiogenesis may improve patient's outcome in CTCL. Usability of these markers into patient's stratification should be considered in further studies.
Identifiants
pubmed: 32606882
doi: 10.2147/CCID.S256269
pii: 256269
pmc: PMC7320895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
431-442Informations de copyright
© 2020 Zohdy et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Dermatol. 2000 Sep;27(9):576-82
pubmed: 11052233
Int J Dermatol. 2020 Mar;59(3):352-358
pubmed: 31647120
PLoS One. 2020 Jan 24;15(1):e0228046
pubmed: 31978091
Pathology. 2017 Feb;49(2):166-171
pubmed: 28065411
Leukemia. 2019 May;33(5):1231-1242
pubmed: 30518812
Br J Dermatol. 2007 Jan;156(1):1-10
pubmed: 17199560
PLoS One. 2015 Apr 17;10(4):e0123435
pubmed: 25885288
J Cutan Pathol. 2013 Apr;40(4):397-404
pubmed: 23379648
J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1517-23
pubmed: 25600184
Postepy Dermatol Alergol. 2015 Dec;32(6):437-42
pubmed: 26755907
Am J Dermatopathol. 2015 Nov;37(11):834-40
pubmed: 26262921
Am J Hematol. 2009 Jun;84(6):338-43
pubmed: 19384938
Oncol Lett. 2019 May;17(5):4060-4067
pubmed: 30944599
Curr Cancer Drug Targets. 2011 Nov;11(9):1030-43
pubmed: 21933106
Blood Res. 2016 Jun;51(2):127-32
pubmed: 27382558
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1967-1971
pubmed: 29569785
Am J Dermatopathol. 2000 Apr;22(2):140-3
pubmed: 10770434
Anticancer Res. 2016 Sep;36(9):4575-82
pubmed: 27630298
Dermatology. 2015;231(1):82-6
pubmed: 26044542
Pathol Oncol Res. 2004;10(1):34-6
pubmed: 15029259
Neoplasia. 2013 Mar;15(3):231-8
pubmed: 23479502
Dermatology. 2006;213(1):15-22
pubmed: 16778421
F1000Res. 2016 Jul 28;5:
pubmed: 27540476
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2
pubmed: 24438969
Acta Derm Venereol. 2017 Feb 8;97(2):235-241
pubmed: 27545193
Clin Lab Med. 2017 Sep;37(3):527-546
pubmed: 28802499
Anticancer Res. 2015 Nov;35(11):6017-26
pubmed: 26504025
Blood. 2019 Sep 26;134(13):1112
pubmed: 31558559
Blood. 2006 Feb 15;107(4):1255-64
pubmed: 16210342
Oncoimmunology. 2017 Mar 17;6(5):e1306618
pubmed: 28638728